TICKERNOMICS Sign up
Last Update: 2023-12-23 06:01:03
Mineralys Therapeutics Inc. ( MLYS )
7.47USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
MLYS
0.00%
SPY
30.72%
MLYS
0.00%
SPY
112.82%
MLYS
0.00%
SPY
201.04%
MLYS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
307.06
147.10
0.10
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.43
0.00
1.16
0.00
0.00
-2.20
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-184.86
-148.02
0.00
Other Earnings and Cash Flow Stats:
Mineralys Therapeutics Inc. ( MLYS ) Net Income TTM ($MM) is -51.12
Mineralys Therapeutics Inc. ( MLYS ) Operating Income TTM ($MM) is -58.64
Mineralys Therapeutics Inc. ( MLYS ) Owners' Earnings Annual ($MM) is 0.00
Mineralys Therapeutics Inc. ( MLYS ) Current Price to Owners' Earnings ratio is 0.00
Mineralys Therapeutics Inc. ( MLYS ) EBITDA TTM ($MM) is -58.64
Mineralys Therapeutics Inc. ( MLYS ) EBITDA Margin is 0.00%
Capital Allocation:
Mineralys Therapeutics Inc. ( MLYS ) has paid 0.00 dividends per share and bought back -2.048465 million shares in the past 12 months
Mineralys Therapeutics Inc. ( MLYS ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Mineralys Therapeutics Inc. ( MLYS ) Interest-bearing Debt ($MM) as of last quarter is 0
Mineralys Therapeutics Inc. ( MLYS ) Annual Working Capital Investments ($MM) are -1
Mineralys Therapeutics Inc. ( MLYS ) Book Value ($MM) as of last quarter is 264
Mineralys Therapeutics Inc. ( MLYS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Mineralys Therapeutics Inc. ( MLYS ) has 265 million in cash on hand as of last quarter
Mineralys Therapeutics Inc. ( MLYS ) has 13 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Mineralys Therapeutics Inc. ( MLYS ) has 41 common shares outstanding as of last quarter
Mineralys Therapeutics Inc. ( MLYS ) has 0 million USD of preferred stock value
Academic Scores:
Mineralys Therapeutics Inc. ( MLYS ) Altman Z-Score is 13.39 as of last quarter
Mineralys Therapeutics Inc. ( MLYS ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Mineralys Therapeutics Inc. ( MLYS ) largest shareholder is owning shares at 0.00 ($MM) value
Jon Congleton(an insider) Bought 4250 shares of Mineralys Therapeutics Inc. ( MLYS ) for the amount of $25372.50 on 2023-11-22
25.77% of Mineralys Therapeutics Inc. ( MLYS ) is held by insiders, and 79.41% is held by institutions
Mineralys Therapeutics Inc. ( MLYS ) went public on 2023-02-10
Other Mineralys Therapeutics Inc. ( MLYS ) financial metrics:
FCF:-43.03
Unlevered Free Cash Flow:0.00
EPS:-2.21
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-34.48
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Mineralys Therapeutics Inc. ( MLYS ) :
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.